Cannabidiol (CBD): A Systematic Review of Clinical and Preclinical Evidence in the Treatment of Pain

Cásedas, Guillermo ; Yarza-Sancho, Martín de ; López, Víctor

Resumen: Background/Objectives: Cannabis sativa L. is a plant that has been used for thousands of years for its industrial and medicinal properties. In recent years, there has been a rise in the study of this plant due to its bioactive compounds for pharmaceutical applications. Particularly, cannabidiol has demonstrated analgesic and non-psychoactive properties. The objective of this systematic review is to update and to gather the clinical and preclinical evidence on CBD in pain treatment. Methods: This study was performed following the PRISMA guidelines and using the following search terms “((cannabidiol) NOT (THC)) NOT (tetrahydrocannabinol)) AND (pain treatment)” in PubMed and Web of Science, with the following inclusion criteria: CBD pain treatment without THC in monotherapy, including both clinical and preclinical trials. From the initial sample of more than 500 articles, a total of 40 studies were selected, eliminating duplicate studies from the databases and considering the inclusion and exclusion criteria. On one hand, clinical trials were analyzed using CBD products without THC used in monotherapy, assigning a Jadad score to evaluate the quality/bias of the trials; on the other hand, the main preclinical trials were analyzed, grouping the results into in vivo and in vitro trials. Results: Based on the review conducted, there is sufficient clinical and preclinical evidence of CBD in pain treatment, so CBD could be an effective and safe treatment in reducing pain due to its analgesic and anti-inflammatory properties. These effects appear to be primarily mediated by the activation of TRPV-1, 5HT-1A, and CB1, with emerging therapeutic relevance in the management of osteoarthritis and chronic pain. Conclusions: Although clinical and preclinical research show promising results, clinical evidence is limited, and more studies should be performed in the future with isolated CBD.

Idioma: Inglés

DOI: 10.3390/ph17111438

Año: 2024

Publicado en: Pharmaceuticals 17, 11 (2024), 1438 [14 pp.]
ISSN: 1424-8247

Factor impacto JCR: 4.8 (2024)

Categ. JCR: PHARMACOLOGY & PHARMACY rank: 51 / 352 = 0.145 (2024) - Q1 - T1
Categ. JCR: CHEMISTRY, MEDICINAL rank: 18 / 72 = 0.25 (2024) - Q1 - T1

Factor impacto CITESCORE: 7.7 - Pharmaceutical Science (Q1) - Drug Discovery (Q2) - Molecular Medicine (Q2)

Factor impacto SCIMAGO: 1.019 - Drug Discovery (Q1) - Pharmaceutical Science (Q1) - Molecular Medicine (Q2)

Tipo y forma: Revisión (Versión definitiva)